intepirdine (SB-742457) / Roivant  >>  Phase 2
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
intepirdine (SB-742457) / Roivant
HEADWAY-DLB, NCT02669433 / 2015-005495-19: Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The Study

Checkmark HEADWAY-DLB study
Jan 2018 - Jan 2018: HEADWAY-DLB study
Completed
2b
484
Canada, US, Europe
RVT-101 35 mg, RVT-101 70 mg, Placebo
Axovant Sciences Ltd.
Dementia With Lewy Bodies
12/17
12/17
NCT00224497 / 2005-000979-18: A Dose Ranging Study To Investigate The Efficacy And Safety Of SB-742457 In Alzheimer's Disease

Completed
2a
380
Europe, RoW
SB-742457
GlaxoSmithKline
Alzheimer's Disease
 
 
NCT00348192 / 2006-000468-95: SB-742457 And Donepezil In Alzheimer's Disease

Completed
2
200
Europe, RoW
SB-742457, donepezil
GlaxoSmithKline
Alzheimer's Disease
 
 
NCT00708552 / 2008-000826-37: Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease

Completed
2
576
Europe, RoW
SB-742457, Donepezil, Placebo
GlaxoSmithKline
Alzheimer's Disease
03/10
03/10
NCT00710684 / 2008-000827-25: A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease

Checkmark CTAD 2016
Dec 2016 - Dec 2016: CTAD 2016
Checkmark CTAD 2016
Dec 2016 - Dec 2016: CTAD 2016
Checkmark CTAD 2016
More
Completed
2
682
US, Canada, Europe, RoW
SB-742457 15mg, SB-742457 35mg, Placebo, donepezil 5-10mg
GlaxoSmithKline
Alzheimer's Disease
05/10
11/10
NCT02910102: Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia

Hourglass
Completed
2
38
US
RVT-101 35 mg, Placebo
Axovant Sciences Ltd.
Alzheimer's Disease, Dementia With Lewy Bodies, Parkinson's Disease Dementia
11/17
11/17

Download Options